Monitoring of condylomas is an early evidence of population effectiveness of human papillomavirus (HPV) vaccination programs. If reporting could include HPV typing, the contribution by vaccine HPV types to condyloma burden could be monitored.
A sentinel site for reporting of condyloma including HPV typing was established at the Centre for Sexual Health in Malmö, Sweden. In 2006 to 2009, when there were few HPV vaccines, 621 subjects with condyloma were reported and HPV genotyped.
Ninety-four percent of the condylomas contained genital HPV types. Thirty-five different genital HPV types were identified, with HPV6 (62%), HPV16 (13%), and HPV11 (10%) being the most common. At least 1 of the 4 HPV types in the HPV6/11/16/18 vaccine was detected in 77%. High-risk HPV types were more common in females (45%) than among males (27%) (odds ratio, 1.9; confidence interval, 1.3–2.8). Extended testing among subjects initially negative for HPV found 21 patients with cutaneous types of HPV, including a novel type (HPV153).
This report provides a baseline distribution of HPV types in condylomas before the introduction of an HPV vaccination program in this population. Human papillomavirus typing is feasible in routine condyloma reporting.
A sentinel site for reporting of condyloma observed that 94% had genital human papillomavirus (HPV) types. Thirty-five genital HPV types were identified, with HPV6, HPV16, and HPV11 being the most common.
From the *WHO HPV LabNet Global Reference Laboratory, Department of Clinical Microbiology, University and Regional Laboratories Region Skåne, Malmö, Sweden; †Department of Medical Microbiology, Lund University, Malmö, Sweden; ‡Centre for Sexual Health, Skåne University Hospital, Sweden; §Regional Centre for Infectious Disease Prevention, Malmö, Sweden; and ¶Departments of Laboratory Medicine, Medical Epidemiology, and Biostatistics, Karolinska Institute and Hospital, Stockholm, Sweden
Supported by grants from the World Health Organization, the Swedish Cancer Society, and Cancer Foundation of University Hospital, Malmö, and a fellowship to Hanna Johansson from BioCARE of Lund and of Gothenburg Universities.
JD has participated in the global steering committee of the FUTUREII HPV vaccination trial and has received research grants to his institution from Merck and SPMSD. AJ has been involved in HPV-vaccination trials (Merck).
The other authors have no conflicts of interest.
Correspondence: Ola Forslund, PhD, Department of Medical Microbiology, University Hospital, SUS, Malmö, 205 02 Malmö, Sweden. E-mail: email@example.com.
Received for publication April 18, 2012, and accepted October 23, 2012.